Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › RARE

SR ONE CAPITAL MANAGEMENT, LP position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

SR ONE CAPITAL MANAGEMENT, LP reported holding 137,753 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$4.6M, representing 0.44% of its reported portfolio and ranking #14 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)137.75K sh
Reported value held$4.60M
Portfolio Weight0.44%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SR ONE CAPITAL MANAGEMENT, LP's RARE position evolved

SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in RARE in Q4 2025 at 137,753 shares (US$3.2M). The position peaked in Q2 2026 at 137,753 shares, worth US$4.6M. Across 3 filings, SR ONE CAPITAL MANAGEMENT, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 137,753 shares valued at US$4.6M.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 137.75K $3.17M New
Q1 2026 137.75K $2.89M Hold
Q2 2026 137.75K $4.60M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has SR ONE CAPITAL MANAGEMENT, LP held RARE?

SR ONE CAPITAL MANAGEMENT, LP has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is SR ONE CAPITAL MANAGEMENT, LP's current position in RARE?

As of Q2 2026, SR ONE CAPITAL MANAGEMENT, LP holds 137.75K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $4.60M, representing 0.44% of its reported portfolio and ranking #14.

Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling RARE?

In the latest 13F filing (Q2 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in RARE. The position peaked in Q2 2026 at 137.75K shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.